Google NewsArgenica Therapeutics Limited (ASX:AGN) Share Price Falls 5.56% as Stock Trades Within Daily Range - Kalkine
Argenica Therapeutics Limited (ASX:AGN) Share Price Falls 5.56% as Stock Trades Within Daily Range Kalkine
Argenica Therapeutics (AGN) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXArgenica Therapeutics Ltd (ASX: AGN) Share Price Update: Stock Rises as Health Care Sector Closes Lower - Kalkine
Argenica Therapeutics Ltd (ASX: AGN) Share Price Update: Stock Rises as Health Care Sector Closes Lower Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Small CapsARG007 Shows Significant Neuroprotection in Concussion Study
other announcement
ARG007 (Xaranetide) Completes All Three FDA Requested Assays
other announcement
Why Argenica Therapeutics (ASX:AGN) Shares Are Back in Focus Today? - Kalkine
Why Argenica Therapeutics (ASX:AGN) Shares Are Back in Focus Today? Kalkine
IND Application Advanced With Successful Completion of Assay
other announcement
Clinical Advisory Committee Established to Advance Phase 2b
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Presentations at European Stroke Organisation Conference
other announcement
Argenica Receives $3.97m R&D Tax Incentive Cash Rebate
other announcement
Investor Presentation - Euroz Hartleys Healthcare Conference
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
AI Analysis Reveals Efficacy In Severe Stroke Patients
other announcement
Positive TNK Study Results Fulfil Key FDA Requirement
other announcement
ARG-007 Efficacious Dose Validated in New Preclinical Study
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Investor Presentation - Cannacord Dug & Device Conference
other announcement
Notification regarding unquoted securities - AGN
other announcement
Phase 2 Trial Promising Improvements in Functional Outcomes
other announcement
Date of AGM & Closing Date for Director Nominations
other announcement
Topline Phase 2 Trial Results of ARG-007 in AIS Patients
other announcement
Argenica Appoints Vice President of Regulatory Affairs
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Argenica to Progress Clinical Development in TBI
other announcement